Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.71
-0.37 (-2.30%)
At close: Aug 1, 2025, 4:00 PM
15.10
-0.61 (-3.88%)
After-hours: Aug 1, 2025, 4:41 PM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $2.69 billion as of August 1, 2025. Its market cap has decreased by -38.68% in one year.
Market Cap
2.69B
Enterprise Value
1.97B
1-Year Change
-38.68%
Ranking
Category
Stock Price
$15.71
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $2.69B, an increase of 2,060.80%. That is a compound annual growth rate of 65.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 1, 2025 | 2.69B | -26.08% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | 4.52B | 404.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 664.39B |
| Johnson & Johnson | 396.75B |
| AbbVie | 333.89B |
| AstraZeneca | 232.21B |
| UnitedHealth Group | 226.39B |
| Novartis AG | 224.47B |
| Abbott Laboratories | 219.55B |
| Novo Nordisk | 213.92B |